Literature DB >> 24966949

Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.

Qing Cao1, Kunlin Lu1, Suiping Dai1, Yan Hu1, Weifang Fan1.   

Abstract

The aim of the present study was to investigate the association of the expression of members in the miR-200 family with clinicopathological characteristics and their impacts on overall survival in patients with epithelial ovarian cancer (EOC). Expression levels of members in the miR-200 family, including miR-200a, miR-200b, miR-200c, miR-141, and miR-429, were detected by using miRNA qRT-PCR and in situ hybridization. Associations of their expression with clinicopathological factors and overall survival were statistically evaluated. Among five members in the miR-200 family, the expression levels of miR-200a, miR-200b and miR-200c were significantly higher in EOC tissues than those in normal surface ovarian epithelium tissues, in line with the findings ofin situ hybridization analysis. In addition, tumors with high miR-200a and miR-200 bexpressionwere both more likely to have advanced stage (both P=0.006) and higher grade (P=0.01 and 0.02), whilehighmiR-200 cexpression was onlysignificantly associated with advanced stage disease (P=0.01). Moreover, univariate analysis showed that the patients with high miR-200a, miR-200b and miR-200c expression all correlated with shorter overall survival in EOC patients (all P<0.001). Multivariate statistical analysis further identified miR-200a, miR-200b and miR-200c asindependent prognostic factorsfor EOC (all P=0.01). In conclusion, these findings suggest that miR-200a, miR-200b and miR-200c overexpression may promote the aggressive tumor progression and be recognized as reliable markers to predict the survival in patients with EOCs. The three miRNAs could be attractive therapeutic targets in patients with advanced-stage EOCs.

Entities:  

Keywords:  clinicopathology; epithelial ovarian cancer; miR-200 family; prognosis

Mesh:

Substances:

Year:  2014        PMID: 24966949      PMCID: PMC4069884     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

1.  The biphasic expression pattern of miR-200a and E-cadherin in epithelial ovarian cancer and its correlation with clinicopathological features.

Authors:  Shaohua Xu; Peizhen Xu; Wei Wu; Yangjun Ou; Juan Xu; Guanghua Zhang; Jinping Li; Guofeng Xu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

2.  MicroRNA expression profiles in serous ovarian carcinoma.

Authors:  Eun Ji Nam; Heejei Yoon; Sang Wun Kim; Hoguen Kim; Young Tae Kim; Jae Hoon Kim; Jae Wook Kim; Sunghoon Kim
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

3.  Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study.

Authors:  A Stoyianni; G Pentheroudakis; H Benjamin; A Cervantes; K Ashkenazi; G Lazaridis; N Pavlidis; Y Spector
Journal:  Clin Transl Oncol       Date:  2013-11-27       Impact factor: 3.405

4.  MicroRNA-145 function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer.

Authors:  Wenjing Zhang; Qian Wang; Minglian Yu; Nan Wu; Hui Wang
Journal:  Technol Cancer Res Treat       Date:  2013-08-02

5.  Identifying microRNA/mRNA dysregulations in ovarian cancer.

Authors:  Gregory D Miles; Michael Seiler; Lorna Rodriguez; Gunaretnam Rajagopal; Gyan Bhanot
Journal:  BMC Res Notes       Date:  2012-03-27

Review 6.  MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy.

Authors:  Kenneth K W To
Journal:  J Biomed Sci       Date:  2013-12-20       Impact factor: 8.410

7.  MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression.

Authors:  Pedro M Costa; Maria C Pedroso de Lima
Journal:  Pharmaceuticals (Basel)       Date:  2013-09-30

Review 8.  Current status and evolution of preclinical drug development models of epithelial ovarian cancer.

Authors:  Panagiotis A Konstantinopoulos; Ursula A Matulonis
Journal:  Front Oncol       Date:  2013-12-11       Impact factor: 6.244

9.  MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1.

Authors:  Hanwen Zhang; Qiuyu Wang; Qian Zhao; Wen Di
Journal:  J Ovarian Res       Date:  2013-11-26       Impact factor: 4.234

10.  Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.

Authors:  Hong Zheng; Lina Zhang; Yanrui Zhao; Da Yang; Fengju Song; Yang Wen; Quan Hao; Zhibin Hu; Wei Zhang; Kexin Chen
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

View more
  38 in total

1.  Altered microRNA expression patterns during the initiation and promotion stages of neonatal diethylstilbestrol-induced dysplasia/neoplasia in the hamster (Mesocricetus auratus) uterus.

Authors:  Ramesh Padmanabhan; Isabel R Hendry; Jennifer R Knapp; Bin Shuai; William J Hendry
Journal:  Cell Biol Toxicol       Date:  2017-03-06       Impact factor: 6.691

2.  Prognostic role of miR-200c in various malignancies: a systematic review and meta-analysis.

Authors:  Ke-Cheng Zhang; Hong-Qing Xi; Jian-Xin Cui; Wei-Song Shen; Ji-Yang Li; Bo Wei; Lin Chen
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.

Authors:  M Zuberi; R Mir; J Das; I Ahmad; J Javid; P Yadav; M Masroor; S Ahmad; P C Ray; A Saxena
Journal:  Clin Transl Oncol       Date:  2015-06-11       Impact factor: 3.405

4.  MicroRNAs Regulate Cytokine Responses in Gingival Epithelial Cells.

Authors:  Steven C Y Chen; Christos Constantinides; Moritz Kebschull; Panos N Papapanou
Journal:  Infect Immun       Date:  2016-11-18       Impact factor: 3.441

5.  MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc.

Authors:  Eleni Anastasiadou; Elena Messina; Tiziana Sanavia; Lucia Mundo; Federica Farinella; Stefano Lazzi; Francesca Megiorni; Simona Ceccarelli; Paola Pontecorvi; Francesco Marampon; Cira Rosaria Tiziana Di Gioia; Giorgia Perniola; Pierluigi Benedetti Panici; Lorenzo Leoncini; Pankaj Trivedi; Andrea Lenzi; Cinzia Marchese
Journal:  Cells       Date:  2021-03-01       Impact factor: 6.600

6.  MicroRNA-183 correlates cancer prognosis, regulates cancer proliferation and bufalin sensitivity in epithelial ovarian caner.

Authors:  Huixiao Chen; Ling Zhang; Lili Zhang; Jing Du; Hongying Wang; Bin Wang
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

7.  MiR-338 suppresses the growth and metastasis of OSCC cells by targeting NRP1.

Authors:  Chunxi Liu; Zhiyu Wang; Yi Wang; Wuwei Gu
Journal:  Mol Cell Biochem       Date:  2014-09-10       Impact factor: 3.396

Review 8.  The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.

Authors:  Priya Samuel; David Raul Francisco Carter
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

9.  Calcineurin Gamma Catalytic Subunit PPP3CC Inhibition by miR-200c-3p Affects Apoptosis in Epithelial Ovarian Cancer.

Authors:  Eleni Anastasiadou; Elena Messina; Tiziana Sanavia; Vittorio Labruna; Simona Ceccarelli; Francesca Megiorni; Giulia Gerini; Paola Pontecorvi; Simona Camero; Giorgia Perniola; Mary Anna Venneri; Pankaj Trivedi; Andrea Lenzi; Cinzia Marchese
Journal:  Genes (Basel)       Date:  2021-09-10       Impact factor: 4.096

Review 10.  Clinical significance of microRNA-200 and let-7 families expression assessment in patients with ovarian cancer.

Authors:  Severyn Ferneza; Markiyan Fetsych; Roman Shuliak; Halyna Makukh; Natalia Volodko; Roman Yarema; Taras Fetsych
Journal:  Ecancermedicalscience       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.